Ketamine administration in depressive disorders: a systematic review and meta-analysis
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Introduction Ketamine's efficacy in depressive disorders has been established in several controlled trials. The aim of the present study was to determine whether or not ketamine administration significantly improves depressive symptomatology in depression and more specifically in major depressive disorder (MDD), bipolar depression, resistant depression (non-ECT studies), and as an anesthetic agent in electroconvulsive therapy (ECT) for resistant depression (ECT studies). Secondary outcomes were the duration of ketamine's effect, the efficacy on suicidal ideations, the existence of a dose effect, and the safety/tolerance of the treatment. Methods Studies were included if they met the following criteria (without any language or date restriction): design: randomized controlled trials, intervention: ketamine administration, participants: diagnosis of depression, and evaluation of severity based on a validated scale. We calculated standardized mean differences (SMDs) with 95 % confidence intervals (CIs) for each study. We used fixed and random effects models. Heterogeneity was assessed using the I2 statistic. Results We included nine non-ECT studies in our quantitative analysis (192 patients with major depressive disorder and 34 patients with bipolar depression). Overall, depression scores were significantly decreased in the ketamine groups compared to those in the control groups (SMD = -0.99; 95 % CI -1.23, -0.75; p Conclusion The present meta-analysis confirms ketamine's efficac…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple meta-analyses55–59 have now concluded that intravenous ketamine is effective as a rapid-acting antidepressant for major depressive episodes in both unipolar and bipolar depression”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [59]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity was assessed using the I2 statistic, which represents the percentage of variance due to between-study factors rather than sampling error (Higgins et al. 2003).”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We used fixed effects (Mantel and Haenszel 1959) and random effects models (DerSimonian and Laird 1986) which account for between-study heterogeneity by weighting studies similarly.”
MethodStatistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“We used fixed effects (Mantel and Haenszel 1959) and random effects models (DerSimonian and Laird 1986) which account for between-study heterogeneity by weighting studies similarly.”
MethodBorenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
(2008) · Cited by 3,790
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · cited 1×
“First, we used markers of internal validity from the Cochrane risk of bias tool (Higgins et al. 2011).”
MethodGrand challenges in global mental health
Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., Daar, A. S., Bordin, I. A., Costello, E. J., Durkin, M., Fairburn, C., et al. (2011) · Nature · doi:10.1038/475027a · Cited by 2,043
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 32×
“The aim of this study was to perform a systematic review and meta-analysis of controlled trials to investigate the efficacy of the ketamine’s administration on depressive symptomatology and more specifically in MDD, resistant depression, and bipolar depression and as an anesthetic agent in ECT for resistant depression.”
BackgroundMethodInfluentialDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 21×
“…were assessed by the Hamilton Depression Rating Scale (HDRS) in five studies (Berman et al. 2000; Ghasemi et al. 2014; Kudoh et al. 2002; Valentine et al. 2011; Zarate et al. 2006) and MADRS in four studies (Diazgranados et al. 2010; Murrough et al. 2013; Sos et al. 2013; Zarate et al. 2012).”
BackgroundMethodResultInfluentialRush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870 · cited 1×
“While forecasts predict an increase in the prevalence of mental disorders in the general population worldwide, a nonnegligible proportion of patients do not respond to medication (Calabrese et al. 2008; Rush et al. 2006; Souery et al. 2006).”
BackgroundZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 14×
“Ketamine was also effective when only patients with resistant depression were included (SMD=−1.11; 95 % CI −1.43, −0.79; p<0.01; I2=36.7 % for resistant depression studies vs SMD=−0.84; 95 % CI −1.21, −0.48; p<0.01; I2=0.0 % for other studies).”
BackgroundMethodResultInfluentialMorgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667 · cited 2×
“Moreover, there is some reluctance to use ketamine in clinical practice (at least in France) due to the potential misuse of this drug (Morgan and Curran 2011), and clinical questions remain unclearly answered to date, such as indications, possible adverse events, recommended doses, duration of…”
BackgroundTreatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Calabrese, J. R., Huffman, R. F., White, R. L., Edwards, S., Thompson, T. R., Ascher, J. A., Monaghan, E. T., & Leadbetter, R. A. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00500.x · Cited by 248 · cited 1×
“While forecasts predict an increase in the prevalence of mental disorders in the general population worldwide, a nonnegligible proportion of patients do not respond to medication (Calabrese et al. 2008; Rush et al. 2006; Souery et al. 2006).”
BackgroundVassos, E., Collier, D. A., & Fazel, S. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.31 · Cited by 234
Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 204 · cited 25×
“The aim of this study was to perform a systematic review and meta-analysis of controlled trials to investigate the efficacy of the ketamine’s administration on depressive symptomatology and more specifically in MDD, resistant depression, and bipolar depression and as an anesthetic agent in ECT for resistant depression.”
BackgroundMethodResultInfluential(2013) · PubMed · Cited by 192
Small-Dose Ketamine Improves the Postoperative State of Depressed Patients
Kudoh, A., Takahira, Y., Katagai, H., & Takazawa, T. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200207000-00020 · Cited by 189 · cited 35×
“In the study by Kudoh et al. (Kudoh et al. 2002), ketamine was administered as an anesthetic agent for orthopedic surgery in depressed patients, and haloperidol 5 mg was administrated for treatment of the postoperative confusion, which may have masked psychotic symptomatology due to ketamine administration.”
BackgroundMethodResultInfluentialLevels of evidence: Taking Neurology ® to the next level
Gross, R. A., & Johnston, K. C. (2009) · Neurology · doi:10.1212/01.wnl.0000342200.58823.6a · Cited by 162
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 162
Wang, X., Chen, Y., Zhou, X., Liu, F., Zhang, T., & Zhang, C. (2012) · The Journal of ECT · doi:10.1097/yct.0b013e31824d1d02 · Cited by 157 · cited 14×
“…our quantitative analysis (Abdallah et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Ghasemi et al. 2014; Jarventausta et al. 2013; Kudoh et al. 2002; Loo et al. 2012; Murrough et al. 2013; Sos et al. 2013; Valentine et al. 2011; Wang et al. 2012; Zarate et al. 2012; Zarate et al. 2006).”
BackgroundMethodInfluentialOkamoto, N., Nakai, T., Sakamoto, K., Nagafusa, Y., Higuchi, T., & Nishikawa, T. (2010) · The Journal of ECT · doi:10.1097/yct.0b013e3181c3b0aa · Cited by 149 · cited 1×
“Overall, depression scores were significantly improved in the 58 patients receiving ketamine in ECT anesthesia induction compared to the 60 patients (SMD=−0.56; 95 % CI −1.10, −0.02; p=0.04; I2=52.4 %).”
BackgroundInfluentialLoo, C. K. A., Katalinic, N., Garfield, J. B. B., Sainsbury, K., Hadži-Pavlović, D., & MacPherson, R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.032 · Cited by 142 · cited 13×
“…our quantitative analysis (Abdallah et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Ghasemi et al. 2014; Jarventausta et al. 2013; Kudoh et al. 2002; Loo et al. 2012; Murrough et al. 2013; Sos et al. 2013; Valentine et al. 2011; Wang et al. 2012; Zarate et al. 2012; Zarate et al. 2006).”
BackgroundMethodInfluentialKrystal, A. D. (2003) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.15.1.27 · Cited by 123 · cited 4×
“The DSM diagnosis was completed by validated scales for inclusion criteria to evaluate baseline severity (four used a Montgomery-Asberg Depression Rating Scale (MADRS) score ≥20 (Diazgranados et al. 2010; Krystal et al. 2003; Sos et al. 2013; Zarate et al. 2012; Zarate et al. 2006), and one a mini-mental status examin…”
BackgroundMethodInfluentialRapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah, C. G., Fasula, M., Kelmendi, B., Sanacora, G., & Ostroff, R. (2012) · The Journal of ECT · doi:10.1097/yct.0b013e31824f8296 · Cited by 123 · cited 12×
“Nine non-ECT studies (conducted between 2000 and 2013) and four ECT studies (conducted in 2012 and 2013) were included in our quantitative analysis (Abdallah et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Ghasemi et al. 2014; Jarventausta et al. 2013; Kudoh et al. 2002; Loo et al. 2012;…”
BackgroundMethodInfluentialJärventausta, K., Chrapek, W., Kampman, O., Tuohimaa, K., Björkqvist, M., Häkkinen, H., Yli-Hankala, A., & Leinonen, E. (2013) · The Journal of ECT · doi:10.1097/yct.0b013e318283b7e9 · Cited by 97 · cited 8×
“Delays between ketamine administration (before the first ECT session) and first mood evaluation were highly heterogeneous 24 h (Wang et al. 2012), 24 to 72 h (Abdallah et al. 2012), after three ECT sessions (Jarventausta et al. 2013), and 1 week (Loo et al. 2012).”
BackgroundMethodInfluentialMcDaniel, W. W., Sahota, A. K., Vyas, B. V., Laguerta, N., Hategan, L., & Oswald, J. (2006) · The Journal of ECT · doi:10.1097/00124509-200606000-00005 · Cited by 94 · cited 2×
“Nine non-ECT studies (conducted between 2000 and 2013) and four ECT studies (conducted in 2012 and 2013) were included in our quantitative analysis (Abdallah et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Ghasemi et al. 2014; Jarventausta et al. 2013; Kudoh et al. 2002; Loo et al. 2012;…”
BackgroundMethodLong-Term Maintenance With Intramuscular Ketamine for Treatment-Resistant Bipolar II Depression
Cusin, C., Hilton, G. Q., Nierenberg, A. A., & D, M. F. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020219 · Cited by 69 · cited 1×
“Another form of administration (intramuscular administration) has recently been used and may improve the treatment feasibility in daily practice (Cusin et al. 2012; Harihar et al. 2013).”
BackgroundIntramuscular ketamine in acute depression: A report on two cases
Harihar, C., Dasari, P., & Srinivas, J. (2013) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.111461 · Cited by 36
Kranaster, L., Hoyer, C., Janke, C., & Sartorius, A. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.647833 · Cited by 30 · cited 2×
“2012; Diazgranados et al. 2010; Kranaster et al. 2011; Kudoh et al. 2002; Murrough et al. 2013; Okamoto et al. 2010; Wang et al. 2012; Zarate et al. 2012).”
BackgroundKetamine (“Ketalar”): A Safer Anaesthetic for ECT
Brewer, C. L., Davidson, J. R. T., & Hereward, S. (1972) · The British Journal of Psychiatry · doi:10.1192/bjp.120.559.679 · Cited by 25 · cited 2×
“…with preliminary evidence suggesting that ketamine anesthesia in ECTmay improve seizure duration relative to other anesthetic agents that are commonly used and minimize side effects, particularly cognitive impairment (Brewer et al. 1972; Green 1973; Krystal et al. 2003; McDaniel et al. 2006).”
BackgroundEffects of Ketamine on In Vivo Cardiac Sympathetic Nerve Endings
Kitagawa, H., Yamazaki, T., Akiyama, T., Mori, H., & Sunagawa, K. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200110001-00009 · Cited by 9
Ketamine As an Anaesthetic for Ect
Green, C. D. (1973) · The British Journal of Psychiatry · doi:10.1192/bjp.122.1.123-a · Cited by 8 · cited 2×
“…with preliminary evidence suggesting that ketamine anesthesia in ECTmay improve seizure duration relative to other anesthetic agents that are commonly used and minimize side effects, particularly cognitive impairment (Brewer et al. 1972; Green 1973; Krystal et al. 2003; McDaniel et al. 2006).”
Background
Cited by
Suicide and suicidal behaviour
Turecki, G., & Brent, D. A. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00234-2 · Cited by 2,338
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“The first identified nine non-ECT studies including 192 patients with major depressive disorder (Fond et al., 2014), with an effect size for short-term reduction in depressive symptoms of −0.”
BackgroundAdult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Metadata
- Authors
- Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., Roger, M., Leboyer, M., & Boyer, L.
- Affiliations
- Inserm (FR)
- Hôpital Sainte-Marguerite (FR)
- Corresponding author
- Fond, Guillaume
- ORCID
- Venue
- Psychopharmacology
- Published
- 2014-07-20
- Volume
- 231
- Issue
- 18
- Pages
- 3663-3676
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2044440339
- Cited by
- 339
- References
- 39
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 33 · 2021: 22 · 2020: 40 · 2019: 27 · 2018: 23 · 2017: 36 · 2016: 41 · 2015: 40 · 2014: 9
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-IDEX-0004)
- Institut National de la Santé et de la Recherche Médicale
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, depression, major depressive disorder, bipolar depression, treatment-resistant depression, electroconvulsive therapy, anesthesia induction, suicidal ideation, antidepressant efficacy, dose-response relationship, drug-free patients
- MeSH terms
- Anesthetics, Dissociative, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Electroconvulsive Therapy, Humans, Ketamine, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.